Laboratorio de Imunofamacologia, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Br J Pharmacol. 2020 Sep;177(17):3898-3904. doi: 10.1111/bph.15164. Epub 2020 Jul 8.
Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation are now known. Overall, mediators of resolution tend to decrease inflammatory responses and provide normal or greater ability of the host to deal with infection. In the lung, it seems that pro-resolution molecules, or strategies that promote their increase, tend to suppress inflammation and lung injury and facilitate control of bacterial or viral burden. Here, we argue that the demonstrated anti-inflammatory, pro-resolving, anti-thrombogenic and anti-microbial effects of such endogenous mediators of resolution may be useful in the treatment of the late stages of the disease in patients with COVID-19.
炎症通常被认为是宿主防御系统的一个组成部分，也是感染性疾病背景下的一种保护反应。然而，改变的炎症反应可能会导致感染个体的疾病。现在已经知道许多驱动炎症消退的内源性介质。总的来说，消退介质往往会降低炎症反应，并为宿主提供正常或更高的能力来应对感染。在肺部，似乎促消退分子，或促进其增加的策略，往往会抑制炎症和肺损伤，并有助于控制细菌或病毒负担。在这里，我们认为，这些内源性消退介质所表现出的抗炎、促消退、抗血栓形成和抗微生物作用，可能对治疗 COVID-19 患者疾病的晚期阶段有用。
Zotero 插件